Introduction {#sec1}
============

The probiotics are live microorganisms that, when administrated in adequate doses, confer a health benefit to the host as defined by the Food and Agriculture Organization of the United Nations and the World Health Organization ([@bib61]). For this purpose, lactic acid bacteria (LAB) have been used for a very long time. At the beginning of the twentieth century, Ilja Metchnikoff suggested that the longevity of Bulgarians is due to consumption of fermented milk products ([@bib52]). Another scientist, Henry Tissier observed that in stools from children with diarrhea, only a small number of bacteria with Y-shaped morphology was present, while in healthy children, a large amount was observed ([@bib85]). In 1965, Lilly and Stillwell used term "probiotic" to describe substances that were secreted by one organism and stimulated the growth of another ([@bib45]).

Probiotic properties have been observed in many genera of bacteria and fungi, but the most commonly used probiotics belong to the species of *Lactobacillus* and *Bifidobacterium*. In addition, other bacteria genera, like *Streptococcus*, *Enterococcus*, and *Bacillus*, as well as members of the yeast genus *Saccharomyces* can have probiotic properties ([@bib32]). The most common species include: *Lactobacillus acidophilus*, *Lactobacillus johnsonii*, *Lactobacillus gasseri*, *Lactobacillus casei*, *Lactobacillus rhamnosus*, *Lactobacillus plantarum*, *Bifidobacterium longum*, *Bifidobacterium breve*, *Bifidobacterium bifidum* and *Bifidobacterium infantis* ([@bib37]). Some bacteria, not regularly present in the gastrointestinal tract, like *Lactobacillus bulgaricus*, *Streptococcus thermophilus*, *Leuconostoc* and *Lactococcus* species may also belong to the category of probiotic microorganisms and are usually used as starters in dairy products ([@bib37]). Most probiotic species, including lactobacilli, *Bifidobacterium*, lactococci, and some yeasts, are classified as the "generally recognized as safe" (GRAS). But there are groups of organisms, like streptococci, enterococci, *Bacillus* and other spore-forming bacteria, that do not possess GRAS status but have been used as probiotics ([@bib77]). It should be noticed that not all bacteria of a given genus or species have probiotic features, they are assigned only to specific strains ([@bib33]). The origin of the strain, resistance to antibiotics, as well as the lack of pathogenicity determines the safety of probiotic strains (Markowiak and Śliżewska 2017).

The term "probiotic" can refer to the following products: probiotic drugs (medicinal products -- live biotherapeutics products for human use), medical devices, probiotic foods (e.g. foods, food ingredients, dietary supplement or food for special medical purposes), directly fed microorganisms (for animal use) and genetically modified probiotics ([@bib93]). Probiotics have an annual market growth of 7% globally ([@bib38]; [@bib51]) and are projected to grow to \$65 billion in 2024 ([@bib27]). Guidance is required to assess the safety of probiotics, but several issues should be taken into account before, i.e., a large variety of probiotic strains, the risks associated with the use of unclassified strains, and the possibility of unsurpassed interactions between both the strains used and the host and bacteria ([@bib28]). Probiotics may be responsible for systemic infections (Marteau 2001; [@bib22]), excessive immune stimulation in susceptible individuals (Marteau 2001; [@bib11]; [@bib22]), deleterious metabolic effects (Marteau 2001; [@bib22]) or gene transfer (Marteau 2001; [@bib5]; [@bib22]). The factors that must be considered in assessing the safety of probiotic products should include infectivity, pathogenicity, an excessive immune stimulation in susceptible individuals, virulence factors comprising toxicity, metabolic activity and the important properties of microbes ([@bib37]). The Lactic Acid Bacteria Industrial Platform has submitted reports from the European Union indicating that except for enterococci the risk of infections caused by lactic acid bacteria is very low ([@bib46]).

Infections {#sec2}
==========

The *Lactobacillus* strains are present in healthy humans in the oral cavity, ileum and colon; moreover, they are the main microorganisms in the vagina ([@bib11]). The *Lactobacillus* and *Bifidobacterium* strains as commensals of human microbiome are safe and nonpathogenic. There is no evidence that consumption of probiotic lactobacilli or bifidobacterial strains poses the risk of infection greater than that related to commensal strains. The number of cases of infection caused by *Lactobacillus* or *Bifidobacterium* strains are very low and vary between 0.05--0.4% for infective endocarditis and bacteremia ([@bib11]). The translocation of bacteria may be caused by a weakened intestinal barrier, resulting in the passage of bacteria across the mucus membrane and epithelium ([@bib8]). The next step is transport of microorganisms through the tunica propria to the mesenteric lymph nodes and other organs ([@bib37]). This translocation may result in bacteremia, followed by multiple organ failure and septicemia ([@bib9]; [@bib91]). Various factors such as damage of the mucous membrane, disturbances in the composition of the intestinal microflora, or diminishing of the host's immune system may stimulate the translocation of the intestinal bacteria ([@bib37]). In some clinical reports, probiotic bacteria have been identified as casual factors of dental cavities, endometritis ([@bib6]), urinary tract infections ([@bib15]; [@bib21]), meningitis ([@bib74]) and spleen abscesses (Sherman et al. 1981). These infections can be associated with recent surgery, organ transplant, AIDS ([@bib60]; [@bib35]; [@bib42]; [@bib3]), valvopathy, diabetes mellitus, immunosuppressive cancer therapy or cancer with antibiotic treatment, which may contribute to selection of specific microorganisms ([@bib46]). Increased consumption of products containing probiotic bacteria has not led to an increase of the aforementioned opportunistic infections in consumers ([@bib11]). In an epidemiological study of *Lactobacillus* bacteremia frequency in Finland, no correlation was found between the increased use of *L. rhamnosus* GG and the occurrence of *Lactobacillus* bacteremia during 1990--2000 ([@bib66]).

The cases of children infections, including bacteremia, caused by the *Lactobacillus* strains are quite rare and have been observed mainly in immunocompromised children ([@bib6]; [@bib39]; [@bib71], [@bib42]), and in patients with neonatal sepsis and meningitis ([@bib14]; [@bib84]), pneumonia ([@bib78]), and also local suppurative infections ([@bib13]). Probiotic therapy administered to preterm infants and neonates should be considered carefully, since at birth infants do not have a fully developed immune system, and thereby after probiotic administration the risk of fungemia or bacteremia significantly increases ([@bib12]; Marodi 2006). *Lactobacillus* bacteremia among children is very unusual, however, there were reports on three infants with short-bowel syndrome that developed bacteremia after consumption of *L. rhamnosus* GG ([@bib41]; [@bib19]). [@bib42] reported two pediatric patients who had ingested probiotic strain *L. rhamnosus* GG and subsequently developed bacteremia and sepsis due to infection with *Lactobacillus* species. [@bib88] described a case of *Lactobacillus* bacteremia in a 17-year-old boy with ulcerative colitis after ingestion of *L. rhamnosus* GG. The 16S rRNA genes similarity was 99.78% between the *L. rhamnosus* strain isolated from the patient's blood and the consumed probiotic strain. This information suggests that people with ulcerative colitis are potentially at the risk of bacteremia due to the *Lactobacillus* strains ([@bib88]). Analysis of the results of 74 different controlled clinical trials showed that the use of probiotic and symbiotic in children between 0 and 18 years old was not linked to an increased health risk ([@bib89]). *L. rhamnosus* and *L. casei*, which are commonly present in the commercial probiotic products, belong to the strains most frequently isolated during bacteremia caused by *Lactobacillus* bacteria ([@bib65]). These *Lactobacillus* species may have a greater potential to translocate and therefore, they could be more pathogenic than other species ([@bib46]). Other probiotic microorganisms directly related to bacteremia and endocarditis are: *L. plantarum*, *L. paracasei*, *L. salivarius*, *L. acidophilus* and many other lactobacilli. Moreover, *Lactococcus lactis*, *Leuconostoc*, *Pediococcus* and *Bifidobacterium* have also been shown to induce bacteremia and endocarditis ([@bib77]). The studies by Harty and coworkers ([@bib31]; [@bib30]) showed that *L. rhamnosus* strains, isolated from patients with endocarditis, possess capability to aggregate platelets and to adhere to fibronectin, fibrinogen and collagen. This aggregation could be related to proteins of the intestinal epithelium. In addition, *L. rhamnosus* and *L. paracasei* subsp. *paracasei* produce enzymes that degrade human glycoproteins and fibrin clots, and this observation suggests that these molecules may participate in the development of infective endocarditis ([@bib46]). [@bib40] described a case of sepsis caused by *L. rhamnosus* in a woman with a heart valve. A bacterial translocation probably occurred by a leaky intestinal barrier and led to heart failure in this patient ([@bib40]). Some cases of *Lactobacillus*-related bacteremia have been reported, including *L. rhamnosus* GG, *L. casei* and *L. acidophilus* ([@bib19]; [@bib43]; [@bib88]). Moreover, nine cases of sepsis have been described, associated with *S. boulardii, L. rhamnosus* GG, *Bifidobacterium breve*, *Bacillus subtilis* or combination of probiotic bacteria ([@bib22]). Fungemia, caused by *Saccharomyces cerevisiae* var. *boulardii* is the most commonly reported single infection (33 reports) ([@bib22]). Among 89 strains from blood samples, analyzed by pulse-field gel electrophoresis, eleven strains had identical PFGE patterns as the probiotic strain *L. rhamnosus* GG ([@bib65]). However, the other studies showed that pathogenic *L. rhamnosus* GG-like strains isolated from the blood cultures, were phenotypically different from probiotic *L. rhamnosus* GG ([@bib59]). Cases of deaths of healthy people caused by the intake of probiotic bacteria are very rare. The percentage of lethal infections caused by *Lactobacillus* is very low; however, these bacteria may infrequently cause bacteremia or endocarditis ([@bib22]).

The probiotic strains have different antimicrobial susceptibility. The high doses of penicillin or ampicillin with or without aminoglycosides are most often used in treatment of lactobacilli infections. The retrospective study of 45 cases of bacteremia, demonstrated that 100% of lactobacilli were susceptible to ampicillin, clindamycin and erythromycin, 96% were susceptible to penicillin and 67% to gentamycin ([@bib75]). On the other hand, bifidobacteria are generally susceptible to β-lactams, glycopeptides and erythromycin ([@bib56]), while fungemias caused by *Saccharomyces* strain may be treated with fluconazole, amphotericin B or voriconazole ([@bib16]).

Stimulation of the immune system {#sec3}
================================

Probiotic strains may modulate the immune response of individuals, and this may result in the increased response to vaccines or allergens. Besides, these strains also have an effect on both cellular and humoral responses, and affect the secretion of cytokines ([@bib72]). Side effects, such as fever or arthritis, can be caused by the presence of peptide-glycan-polysaccharides, which are components of the bacterial cell wall, e.g. of the *Lactobacillus* genus (Marteau 2001). The immune system of healthy and immunocompromised individuals may react differently to probiotic bacteria. For example, probiotic bacteria may exert a stimulating effect on phagocytosis in healthy people, whereas for people with allergies, this effect can be opposite ([@bib72]). The immunomodulatory effect can also depend on the dose of probiotic used ([@bib86]). Despite the lack of direct reports on the probiotics harmful for immunocompromised individuals, it seems important to continue research on the efficacy and safety of probiotics ([@bib68]; [@bib22]).

Detrimental metabolic effect {#sec4}
============================

Probiotic bacteria during colonization of the small bowel deconjugate and dehydroxylate bile salts what could results in diarrhea and intestinal lesions ([@bib2]). Since probiotic strains can produce bile salt hydrolase (BSH), the deconjugated bile salts could be accumulated, and then altered into harmful secondary bile acids by intestinal microbiota. The accumulation of these cytotoxic compounds in the enterohepatic circulation could increase the risk of cholestasis and colorectal cancer ([@bib80]). The harmful effects exerted by BSH on humans have not yet been accurately described ([@bib58]). The probiotic *L. acidophilus* and *Bifidobacterium* spp., the strains derived from fermented milk products, may also convert the primary bile salts to secondary bile salts. If decarboxylation and dehydroxylation processes occur in excess, then there may be a potential risk to the patient's health ([@bib63]).

Other deleterious metabolic effect is D-lactate production by probiotic strains ([@bib22]). Humans produce the L(+)-isomer of lactic acid, while the presence of D(--)-lactate is the result of bacterial metabolism or transformation of L(+)-lactate by a bacterial DL-lactate racemase ([@bib36]; [@bib68]). Some of the *Lactobacillus* strains may produce L(+)-lactic acid as well as D(--)-lactic acid and transform one isomer into the other ([@bib94]). In healthy humans, the increased level of D-lactic acidosis is rarely observed ([@bib94]), but in children with short bowel syndrome the blood concentration of D-lactic acid is high during an exacerbation of symptoms ([@bib10]; [@bib68]). Five reports of D-lactic acidosis can be found in the literature ([@bib22]), of which two concern the patients with short bowel syndrome, both proceeded by the administration of probiotics ([@bib48]). Infants may be more vulnerable to D-lactic acidosis, because of weaken barrier function of the intestinal tract and reduced ability of renal excretion ([@bib68]; [@bib48]). In patients at risk of developing D-lactic acidosis, especially those with former bowel surgery and subsequent gut syndrome, and in newborns and neonates, administration of probiotics which may produce D(--)-lactate should be handled very carefully ([@bib68]).

Probiotic deleterious metabolic activities, such as degradation of mucin may also contribute to potential side effects after their consumption. In this case, the number of microorganisms that translocate through the small bowel is increased, possibly causing gastrointestinal disturbances including intestinal inflammation. One hypothesis states that the accumulation of probiotics in the gastrointestinal tract could result in increased risk of intestinal mucus degradation, but it was not confirmed. [@bib63] conducted experiments on germ-free rats. They studied the degradation of mucus glycoprotein by *Lactobacillus casei* strain GG, *L. acidophilus*, *B. bifidum* and lactic culture isolated from fermented products, but did not observe any degradation of intestinal mucus glycoproteins or damage of the intestinal mucus layer ([@bib63]). Moreover, [@bib1] did not observe translocation, damage of epithelial cells or any changes of the mucosal layer in the ileum, cecum and colon.

Potential transfer of genes {#sec5}
===========================

Another aspect concerning the safety of bacteria used as probiotics is the potential transfer of the antibiotic resistance genes between probiotics and other commensal or pathogenic bacteria that occur in the gastrointestinal tract ([@bib83]; [@bib67]; [@bib77]; [@bib57]). It has been reported that over 68% of probiotic strains were resistant to two or more antibiotics. Moreover, *Bacillus* strains from some probiotic products display even a high-level resistance. Lactic acid bacteria are naturally resistant to some antibiotics ([@bib28]). Many lactobacilli strains, apart from *L. delbrueckii* subsp. *bulgaricus*, *L. acidophilus*, *L. johnsonii* and *L. crispatus* are naturally resistant to vancomycin ([@bib17]; Balletti et al. 2009; [@bib47]; [@bib73]; [@bib29]); however, the genes responsible for this resistance are chromosomally located and not easily transferable to other genera ([@bib87]; [@bib73]). *Lactobacillus* species are often resistant to aminoglycosides, monobactams and fluoroquinolones ([@bib96]). [@bib29] reported that 70% of the *Lactobacillus* strains tested were resistant to ciprofloxacin. The resistance of LAB strains to tetracycline, erythromycin, chloramphenicol, streptomycin, lincosamides and streptogramins may be due to the presence of plasmids bearing the genes encoding resistance to these antibacterial agents ([@bib22]). The most commonly found resistance genes in *Lactobacillus* species are *tet*(M) and *erm*(B), responsible for tetracycline and erythromycin resistance, respectively. Moreover, the *cat* gene encoding chloramphenicol acetyltransferase was also present in LAB ([@bib24]). The *tet*(M) genes localized in *Lactobacillus* strains of various species, derived from fermented food possess a high similarity to the genes present in the pathogenic meningococcal or *Staphylococcus aureus* strains ([@bib25]; [@bib26]). The resistance plasmids carrying the *tet*(M) and *erm*(B) genes have been found in *L. reuteri*, *L. fermentum*, *L. acidophilus* and *L. plantarum* isolated from raw meat, silage and feces of animals ([@bib77]). The isolates of *Leuconostoc* and *Pediococcus* can accept broad host range antibiotic resistance plasmids from *Lactococcus* species ([@bib20]). Moreover, *in vitro* conjugation transfer may occur from *Enterococcus* to *Lactococcus* and *Lactobacillus* ([@bib22]). In some *Lactobacillus* strains (e.g., *L. plantarum*, *L. reuteri*, *L. fermentum*) a transmission of antibiotic resistance genes to other LAB strains occur via the pAMβ plasmid ([@bib70]). Analysis of gene transfer from 44 strains of *L. acidophilus*, 14 strains of *L. delbrueckii*, six strains of *L. casei rhamnosus*, five strains of *L. plantarum*, one strain of *L. helveticus*, one strain of *L. brevis* and one strain of *L. fermentum*, showed that only a single strain of *L. helveticus* and one *L. brevis* accepted the plasmid with low efficiency ([@bib55]). [@bib79] compared the genes from three bacterial isolates derived from dairy products containing the *L. rhamnosus* GG strains with a reference strain from the ATCC collection (*L. rhamnosus* 53103). In two of three strains tested, the lack of DNA fragments encoding 34 and 84 genes that affect the adhesion of these strains and their persistence in the gastrointestinal tract was observed ([@bib79]). These examples underline the potential for genetic variation in LAB and other probiotic bacteria, and suggest that these changes may occur in the microbial cultures used for commercial processes ([@bib69]).

The risk of transfer of antibiotic resistance genes may be an argument against use of probiotic, for example in aquaculture. On the other hand, some antibiotic resistance phenotypes, for example resistance of few lactobacilli strains to vancomycin ([@bib87]), or resistance represented by *Streptomyces* strains, are not easily transferable to other genera ([@bib81]). Bacterial strains used as probiotic drugs, foods or dairy products should be systematically controlled in order to detect the antibiotic resistance genes that could be transferable to pathogenic bacteria. According to the guidelines of European Food Safety Authority (EFSA) all bacterial strains, used as feed additives, should be tested to determine their sensitivity to commonly used antibiotics ([@bib23]).

Identification {#sec6}
==============

The correct identification of strains is extremely important for safety, growth conditions and metabolic properties of a given strain ([@bib62]). The correct classification of strains in a microbiome is extremely important at the time of preparation of the probiotic since this information is crucial for assessment of the stability of the strain, and to perform comparison with clinical isolates in the case of infection ([@bib68]). Even if the strain of probiotic bacteria is considered as safe, it still can cause bacteremia ([@bib90]) as opportunistic bacteria.

Microbiological examination of probiotic products showed that they might contain some microorganisms that were not indicated on the label ([@bib34]; [@bib82]; [@bib18]; Millazzo et al. 2004; [@bib49]; [@bib95]). The presence of these microorganisms indicates an inadequate control of production or insufficient control procedures. Some of the available probiotic products are labeled poorly, with lack of information not only on the classification of the strains included, but also about the excipients present in product, such as cow's milk protein, which may be an allergen for some people ([@bib54]; [@bib44]).

Conclusion {#sec7}
==========

The major risk factor in safe applications of probiotic microorganisms is the lack of knowledge on their activity. The interactions between intestinal microbes and the host have a major influence on the overall health condition. The suitable characteristics of relationships between probiotic structure and function would reduce the possibility of side effects. Generally, probiotic bacteria have a beneficial effect on the digestive system but in some cases they may facilitate the translocation or induce infections themselves. Due to the fact that the adverse effects caused by probiotics are documented, it is necessary to fully understand the mechanisms of activity of probiotic bacteria. In addition, the differences in activity of a single strain or a mixture of strains of different species or even genera should also be taken into account before the probiotic use in humans ([@bib68]).
